MGMT and neoplasm: Once glioblastoma patients are dichotomized into highly and moderately vascularized tumor subgroups using rCBV, we observe a highly significant impact of MGMT status in patients with moderately vascularized tumors and only a non-significant trend in patients with highly vascularized tumors.